Summary: Professor Benjamin E Blass received his bachelor of science in chemistry from Emory University in 1990 and his Ph.D. in organic chemistry from the University of Rochester under the direction of Dr. Andrew S. Kende in 1994. Upon completion of his degree, Dr. Blass accepted a position with Procter & Gamble Pharmaceuticals (P&GP) in Cincinnati, OH. During his tenure with P&GP, Dr. Blass had the opportunity to work on and lead programs focused on heart failure, atrial arrhythmia, osteoarthritis, osteoporosis, and type two diabetes. He also took a key role in the development of high throughput chemistry methods and led a team of 12 chemists who provide “flow to work” medicinal chemistry support to programs in need of additional resources. When P&GP suspended research activities in 2006, he relocated to Wyeth Research in Collegeville, PA. As a principal research scientist, he led a team of colleagues focused on the identification of novel Kv1.5 inhibitors useful for the treatment of atrial arrhythmia that culminated in a clinical lead candidate. He also conducted research on estrogen receptor beta antagonists and TRPV1 channel blockers during his time with Wyeth Research. In 2010, Dr. Blass left the Pfizer after their acquisition of Wyeth, spent 9 months at Fox Chase Chemical Diversity Center, a regional biotech start-up company. In December 2010, Dr. Blass joined the faculty at Temple University School of Pharmacy where he is currently an assistant professor of medicinal chemistry. He also completed the registration requirement to become a U.S. patent agent (registration #67006) in November, 2010. In this capacity, he is the sole proprietor of a boutique patent firm, Blass Patent Associates, and consults with the patent law firm Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd. on intellectual property and medicinal chemistry matters.
Research interests: The laboratories of Dr. Blass conducted research in 4 areas, 5-HT7 receptor modulators, D3 dopamine receptor modulators, Sigma-2 receptor modulators, and Glutamate Transporter 1 (GLT-1) expression modulators. The primary goal in each program is the design of novel compound class capable of matriculating into clinical lead candidates.